Composition for detection and/or treatment of lesions & Tumours

Details for Australian Patent Application No. 2012227281 (hide)

Owner Bailey, P.

Inventors Drury, Terry; Kennedy, John Wayne

Agent Walsh & Associates

Pub. Number AU-A-2012227281

Parent 2002322182

Filing date 24 September 2012

Wipo publication date 11 October 2012

International Classifications

A61K 33/30 Medicinal preparations containing inorganic active ingredients - Zinc

A61K 36/00 Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines

A61K 36/185 Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines - Magnoliopsida (dicotyledons)

A61K 36/66 Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines

A61K 36/80 Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines

A61K 49/04 Preparations for testing - X-ray contrast preparations

A61P 35/00 Antineoplastic agents

Event Publications

11 October 2012 Application Open to Public Inspection

  Published as AU-A-2012227281

11 October 2012 Complete Application Filed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2012227282-Protection device, offshore support platform and offshore wind turbine generator system

2012227280-Human cytomegalovirus immunotherapy